GSK, Lilly and Vir Biotechnology achieve positive results in Phase II COVID-19 study

GSK, Lilly, and Vir Biotechnology have recently presented the results of a COVID-19 study. The two monoclonal antibodies in combination have demonstrated a 70% relative reduction in the persistence of a high viral load at seven days of treatment...

GSK, Lilly and Vir Biotechnology achieve positive results in Phase II COVID-19 study
GSK, Lilly, and Vir Biotechnology have recently presented the results of a COVID-19 study. The two monoclonal antibodies in combination have demonstrated a 70% relative reduction in the persistence of a high viral load at seven days of treatment compared to placebo. VIR-7831 is an experimental compound not approved by the FDA or any health authority.